Project Grant R01CA303628
Award Date 8/13/26
Completion Date 7/31/31
Dollars Obligated $607K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc. $645,102 on July 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to support research investigating the molecular mechanisms governing WEE1 kinase transition from CDK inhibitor to substrate in cell cycle control. The project addresses how WEE1 kinase shifts between functioning as an active enzyme and as a substrate for phosphorylation at the G2-to-M cell cycle checkpoint. The work focuses on the N-terminal...
- The National Cancer Institute, within the Department of Health and Human Services, awarded Dana-Farber Cancer Institute, Inc. $718,275 on July 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate context-specific pathway dependencies for nuclear envelope proteins in brain cancer. The research addresses how nuclear envelope-associated proteins perform distinct biochemical functions across different cellular contexts in central nervous system cancers. The project uses an...
- The National Cancer Institute, an office of the Department of Health and Human Services National Institutes of Health, awarded Dana-Farber Cancer Institute, Inc. $657,443 on September 1, 2026, under the Cancer Biology Research program (CFDA 93.396, Assistance Listing R01CA315392). The award funds structural and mechanistic studies of the RAS/RAF MAPKINASE pathway to achieve atomic-resolution understanding of how these proteins recognize and interact with one another and how these interactions...
- The National Cancer Institute awarded Dana-Farber Cancer Institute $683,075 on March 24, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to investigate the mitotic function of the 53BP1 protein and its negative regulator TIRR in maintaining genome stability and regulating DNA double-strand break repair pathways. The award funds research examining how the 53BP1/TIRR complex regulates mitotic fidelity and immune-mediated radiation response. The project brings together...
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc., $144,035 on September 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support research dissecting transcription factor-mediated chromatin remodeling complex activities in human cancer. The funded work integrates biochemistry, structural biology, functional genomics, and chemical biology approaches to define how BAF (mammalian SWI/SNF) chromatin remodeling complexes are recruited by transcription...
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc. $235,491 on May 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support research training and career development in cancer research. The award funds investigation into high-count monoclonal B-cell lymphocytosis (HC-MBL) and its relationship to mosaic chromosomal alterations, particularly deletions in chromosome 13q and trisomy 12. The research will examine phenotypic consequences of HC-MBL across two...
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc. $737,086 on July 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate CDH17 as a therapeutic target in translocation renal cell carcinoma through T cell redirection therapy. The project, titled "From Biology to Therapy: Mechanism-Informed Targeting in Translocation Renal Cell Carcinoma," addresses an unmet medical need in a rare and aggressive RCC subtype driven by TFE3 gene fusion....
- The National Cancer Institute, a component of the Department of Health and Human Services National Institutes of Health, awarded Dana-Farber Cancer Institute, Inc. $134,919 under the Cancer Research Manpower program (CFDA 93.398) on June 11, 2026. The award funds structure-function and mechanistic studies of the protein-O-mannosyl transferase (POMT) complex in pediatric low-grade gliomas driven by the KIAA1549:BRAF fusion. The research aims to determine high-resolution structures of the POMT...
- The National Cancer Institute awarded Dana-Farber Cancer Institute $643,414 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop an interleukin-21 mimic compound, designated 21H10, that enhances anti-tumor immunity in pancreatic ductal adenocarcinoma. The research centers on combining 21H10 with KRAS inhibitors to convert transient therapeutic responses into durable remissions in pancreatic cancer. The compound was developed using AI-assisted computational...
- The National Cancer Institute, a component of the Department of Health and Human Services National Institutes of Health, awarded Beth Israel Deaconess Medical Center, Inc. $524,110 on June 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393, Assistance Listing Project Grant R01CA314254). The award funds research on one-ended break repair mechanisms in mammalian cells, specifically investigating how cells repair DNA damage at broken replication forks and double-strand...